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Abstract 
The chemical modifications of macrolide natural products into aza- or lactam analogues is a 
strategy employed to improve their metabolic stability and biological activity. The methods for the 
synthesis of several lactam analogues of macrolide natural products is highlighted and aspects of 
their biological properties presented. 
 
Keywords: macrolactams, aza-epothilone B, 15-aza-salicylihalamide A, migrastatin lactam, 
radicicol macrolactams 
 
Introduction 
 The utilization of biologically active heterocyclic macrocycles in Nature is a reflection of their 
efficacy and benefit to biological processes. One drug analysis1 has revealed that 59% of small-
molecule drugs contain a ring-nitrogen and most of the approved nitrogen macrocycles are natural 
products or derivatives of natural products. The major liabilities of macrocyclic natural products2  
are in vivo instability and significant toxic side effects. In this regard nitrogen or aza-analogues 
(lactams) often display advantageous properties such as improved reactivity, aqueous solubility, 
bioavailability, metabolic stability and often also reduced toxicity. 
 
 
 
Figure 1. Selected aza analogues of macrolide natural products. 
 
 Macrolide natural products3,4 with 12, 14, or 16 membered rings and their semisynthetic 
derivatives are important clinically relevant compounds predominantly used for the treatment of 
various types of cancer.5 Macrolactams are easily synthesized and offer access to multiple 
analogues with chemical and enzymatic stability6 as well as desirable biological properties. In this 
short review article, the synthesis and biological activity of some key examples of lactam analogues 
of 12, 14, and 16 membered macrolides in which only the oxygen atom is substituted by nitrogen in 
the macrocycle are presented. Examples of aza modified macrolides include the 16-membered 15-
aza-epothilone B or ixabepilone (1), the most successful lactam modified macrolide which has been 
approved for the treatment of aggressive metastatic taxol resistant breast cancer,7 the 12-membered 
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aza-salicylihalamide analogue 2,8 the 14-membered aza-migrastatin9  analogue 3, and the 14-
membered aza-radicicol analogue 4 (Figure 1).10  
 
15-Aza-epothilone B [Ixabepilone] (1) 
 The epothilones A (6) and B (5) (Figure 2) are members of a group of 16-membered bacterial 
macrolides originally identified11 as secondary metabolites produced by the soil-dwelling 
myxobacterium Sorangium cellulosum (strain So ce90) which possesses the largest bacterial 
genome sequenced to date12  (13,033,779 base pairs). Interest in the epothilones increased when it 
was discovered in 1995 that they possess potent tubulin binding properties, rivaling taxol in killing 
dividing cells by inducing tubulin polymerization and enhancing microtubule stability.13 Epothilone 
B (5) shares the same binding site as taxoids,7 however their mode of binding within the binding 
pocket is distinctive.14 In addition to epothilone A and B, a diverse number of natural epothilone 
compounds have been isolated from the same myxobacterium.15 Epothilone B (5) was more potent 
than paclitaxel in inhibiting cell growth.16  
 
Figure 2. Selected biological for ixabepilone (1), epothilone B (5) and epothilone A (6) 
(LCK = log cell kill and IC50 Pat-7 ovarian carcinoma model; PPB = Plasma protein binding)
13c 
  
 Intensive chemical analogue synthesis unveiled structure activity relationships17 for epothilone B 
(5). Fortunately, it was quickly recognized that the lactone group is vulnerable to hydrolytic 
cleavage by esterases which may account for the short half-life of epothilones in the early animal 
studies.18 Further studies resulted in several lead-structures for the discovery of clinical candidates 
for cancer treatment.17 The lactam 15-aza-epothilone B (1) (ixabepilone)19 was identified as a 
potent analogue of epothilone B (5) (Figure 2) and this compound showed high potency against 
ovarian cancer (IC50  = 2.6 nM) and leukemia cell lines (CCRF-CEM: IC50 = 2.1 nM) comparable 
to that for epothilone B (5) (IC50  = 0.41 nM) but was less toxic. Macrolactam 1 was only 10-fold 
lower in activity when compared with epothilone B (5) but also more importantly displayed a 50-
fold decrease in cytotoxicity.13a  In 2007, ixabepilone (1) by Bristol-Myers Squibb (marketed as 
Ixempra), was approved by the FDA for the treatment of aggressive metastatic taxol resistant breast 
cancer.7  Key to its success as a cancer therapeutic agent is the fact that the lactam had better 
metabolic stability (less prone to hydrolysis). Ixabepilone (1) had a metabolic hydrolysis rate 
[mouse S9 liver fraction: 0.01 nmol/(min  mg)] 100 times slower than epothilone B (6) [1.02 
nmol/(min mg)].13c In addition, ixabepilone has increased water solubility, reducing the use of 
formulation agent such as cremophor (polyethoxylated castor oil) which can cause allergic reactions 
in some patients. 
 
 
Scheme 1. Retrosynthetic analysis and key bond connections of ixabepilone (1) 
 
 The convergent retrosynthetic strategy for the first total synthesis of ixabepilone (1) is depicted 
in Scheme 1 and this was utilised by Danishefsky and coworkers.20,21  The key transformations 
involved a late stage epoxidation and a Suzuki coupling and subsequent macrolactamisation to form 
Compound 
 
 Efficacy 
(LCK) 
IC  
IC50 
(nM) 
 
PPB  
(%) 
6 0.1 4.25 76.6 
5 0.4 0.41 92.0 
1 2.1 2.60 79.4 
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the macrolactam 12,13-desoxy-15-aza-epothilone B (aza-dEpoB) (7). This led to the two precursors 
vinyl iodide 8 and β,δ-diketoester 9. 
 
 
Scheme 2. Total synthesis of ixabepilone (1) by Danishefsky et. al.20 
 
 The triethylsilyl protected vinyl iodide 12 was formed in 98% yield via a Horner-Emmons type 
condensation with the readily prepared phosphine oxide 10 and ketone 11 (Scheme 2). Deprotection 
of the TES ether gave an alcohol that was converted into the azide 8 by a Mitsunobu reaction. 
Acylation of β-ketoester 13 followed by methylation gave enol ether 14. Aldol coupling of the 
enolate derived from 14 with S-2-methyl-4-pentenal 15 and protection as the trichloroethyl 
carbonate ester (Troc) then afforded adduct 9. The Pd-catalyzed Suzuki cross-coupling reaction of 
in situ prepared B-alkyl-9-BBN derivative of 9 with the azido vinyl iodide 8 delivered the 
corresponding cis-olefin 16 in 78 % yield. A Staudinger reduction of azide 16 to the amine, primary 
amine protection and enol hydrolysis gave carbamate 17.  The subsequent asymmetric reduction of 
C3 carbonyl group was optimized with a modified Noyori catalyst22  and yielded a single C3-
hydroxy diastereoisomer in 78% yield. Exposure to trifluoroacetic acid deprotected both Boc group 
and tert-butyl ester and macrolactamisation of the resultant amino acid with HATU in 
dichloromethane gave macrolactam 18 in 90% yield. The O7 Troc protecting group was removed in 
88% yield by sonication of 18 in acetic acid and zinc dust to afford aza-dEpoB (7), and epoxidation 
of the C12-13 (Z)-alkene with 2,2-dimethyldioxirane at –50 °C provided a 70% yield of 15-aza-
epothilone B (1) as a single diastereoisomer. Both ixabepilone (1) and Aza-dEpoB (7) showed 
potent activity against human leukemia cells lines (CCRF-CEM) with 1 slightly being more active 
(IC50 = 2.1 and 9.5 nM, respectively). 
 Ixabepilone (1) can also be semi-synthesized from epothilone B (5) and this is close to how the 
material is produced on a large scale for clinical use (Scheme 3).19  Remarkably, macrolide ring 
opening of epothilone B (5) mediated with Pd(PPh3)4 gave the π-allylpalladium complex 19 that 
could be intercepted by an azide nucleophile. The resultant allylic azide 20 was then reduced to the 
amine 21 and cyclized to yield the lactam macrolide 1. Since the natural product epothilone B (5) 
can be produced in quantity through optimized bacterial fermentation,23 this one-pot three-step 
transformation [20-25% overall yield] enables ready access to ixabepilone (1). 
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Scheme 3. Semisynthesis of ixabepilone (1) from epothilone B (5).19 
 
 Molecular energy calculations conducted on epothilone B and ixabepilone24 using the  
MP2//B3LYP method found that the C10-C11-C12-O12 torsion angle directs the exo (epoxide out 
of macrocycle) and endo (epoxide into macrocycle) conformations of the macrocycle. Importantly, 
the macrocycles include either two intramolecular hydrogen bonds for epothilone B (5) or three for 
ixabepilone (1) that accounts for the ring conformations for both lactone/lactam structures. 
Epothilone B (5) prefers to adopt the compact exo conformation 5ex (Figure 3), as a consequence of 
the short, near-linear hydrogen bonding between the 3-hydroxyl group and the side-chain thiazole N 
atom, and from the 7-hydroxyl to the C5-ketone that contribute to the total macrolide conformation 
energy. In contrast, the macrocyclic hydrogen bonding involving the amide group facilitates 
ixabepilone (1) to exist as competitive mixtures of exo (1ex) and endo (1en) conformers enabling 
the slightly less stable endo conformer to energetically compete for the taxol binding site. The 
endo-ixabepilone (1en) conformer thus has cooperative hydrogen bonding between the amide NH, 
the 3-hydroxyl, and the epoxide. This illustrates that the lactone to lactam change induces 
significant conformational flexibility within the macrocyclic structure offering more hydrogen 
bonding patterns and conformational diversity relative to the natural macrolide. This 
conformational mobility may also contribute to low plasma protein binding observed (see Figure 2) 
for ixabepilone (1) which could result in better in vivo efficacy. 
 
Figure 3. Low energy conformers of exo-epothilone B (5ex) and exo and endo-ixabepilone (1) with critical H-bonds 
indicated (reproduced from SI data: see Lozynski24 ) 
 
 The electron crystallography structure of epothilone A (6) bound to zinc-stabilized α,β-tubulin 
was determined14 to a resolution of 2.89 Å and this, along with NMR based conformational 
analysis, revealed that the bound conformation of 6 has the epoxide in the endo orientation (Figure 
exo-Epothilone B (5ex) exo-Ixabepilone (1ex)
relative energy 0.0 kcal mol-1
endo-Ixabepilone (1en)
0.19 kcal mol-1
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4A). Key interactions with Arg276, Thr274 and Arg282 were present along with a H-bond between 
the thiazole nitrogen atom and His227. As shown in the overlay (Figure 4B), the conformation of 
bound epothilone A (6) is very close to that the calculated conformer of ixabepilone (1en) above 
and this may provide an explanation as to why that the macrolactam analogue 1 can effectively 
bind. 
 
 
    A       B 
Figure 4. (A) Surface map of epothilone A (6) (yellow C atoms) bound to zinc-stabilized two-dimensional crystals of 
tubulin showing H-bonds as dashed black lines (produced from electron crystallography structure from PDB code 1tvk 
see Nettles et. al.14). 
(B) Overlay of bound 6 (yellow C atoms) and calculated endo conformer of  ixabepilone (1en)24 (blue C atoms) 
 
12,13-desoxy-15-Aza-epothilone A (22) 
 A total synthesis of the 12,13-desoxy-aza-epothilone A analogue 22 has been reported by 
Schinzer and co-workers25  as shown in Scheme 4. Wittig coupling of ylide 23 and ketone 24 gave 
the diene 25 in high yield after removal of the Boc group.  The acid coupling partner 28 was 
synthesized from ketone 26 and aldehyde 27 via aldol condensation followed by acetal hydrolysis, 
protection and oxidation. Coupling of amine 25 and acid 28 proceeded in good yields using 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP) to afforded diene 
29. RCM using Grubbs I catalyst gave the macrocycle 30 along with the E-isomer as a 1:1 mixture 
and separation followed by deprotection of the TBS ethers afforded 12,13-desoxy-aza-epothilone A 
22 which was active against human epidermoid cancer cell lines KB-31 and KB-8511 (IC50 = 464 
and 285 nM respectively) but was less active than ixabepilone (1) indicating the importance of the 
epoxide. Compound 22 also induced tubulin polymerization at 26% that measured for epothilone B 
(5).25 
 
Scheme 4. Synthesis of 12,13-desoxy-aza-epothilone A analogue (22).25 
 
Arg282
Arg276
Thr274
His227
6
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15-Aza-salicylihalamide analogue 2  
 The salicylate enamide macrolide natural products shown in Figure 5 are potent antitumor 
compounds and mammalian vacuolar type proton ATPase (V-ATPase) inhibitors.26  Inhibition of 
these proton pumps eventually leads to cell death via apoptosis. Salicylihalamide A (31) was 
isolated27  from a sponge of the genus Haliclona and is a novel highly cytotoxic macrolide. The 
myxobacteria metabolite apicularen A28 (32) is a potent cyctotoxin against several human tumor 
cell lines (cervical  IC50 0.4 ngmL
-1; kidney   IC50 0.3 ngmL
-1lung IC50 0.1 ngmL
-1, prostate IC50 0.5 
ngmL-1) and contains the same novel secondary enamide functionality29 as found in 
salicylihalamide A (31).27 It also possesses a similar benzolactone with an internal 9,13-trans-
tetrahydropyran ring and shows highly effective growth inhibition of several human tumor cell 
lines.  
 
Figure 5. Salicylihalamide A (31) and analogues 33 and 2 and apicularen A (32). 
 
 The simplified salicylihalmide analogue 33 also showed potent activity against human tumor 
cells lines [SF268 (CNS glioma), GI50 0.27 µM; DU-145 (prostate cancer) 2.12 µM].
30  The 
discovery and effectiveness of the potent ixabepilone (1) that was found to exhibit a better 
therapeutic range than epothilone B inspired the research into modification of the salicylihalamide 
(31) 12-membered macrolactone into aza-salicylihalamide A analogue 2.  
 
Scheme 5. Synthesis of 15-aza-salicylihalamide A analogue (2).8 
 
 The synthesis of the simplified 15-aza-salicylihalamide A analogue 2 shown in Scheme 5 
involved the following key synthesis steps that are all scalable.8 To form the amide, a 
photochemical acylation reaction31 was utilised in which the quinoketene intermediate 35, formed 
from photolysis of 1,3-dioxanolone 34, was captured by the optically pure amine 36 to yield the 
diene 37 in 65% yield. This method of amide formation was far superior to alternatives involving 
traditional benzoic acid-amine cross couplings. The highest E selectivity in the ring closing 
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metathesis was observed using Grubbs 1st generation catalyst on the acetate protected diene 38 
which gave the lactam 39 in 75% yield. Other protecting groups, such as methyl and silyl based 
ones gave inferior E:Z selectivities in the RCM reaction. PMB group removal gave alcohol 40 and 
oxidation provided aldehyde 41, the structure of which was confirmed by X-ray crystallography. A 
Takai homologation gave the vinyl iodide 42. The final step involved the copper mediated cross 
coupling32  of iodide 42 with dienamide 43 which resulted in the CuI catalyzed attachment of 
enamide side chain giving the aza-salicyliamide analogue 2 in 64% yield. 
 The 15-Aza-salicylihalamide A analogue 2 showed potent activity8  against several leukemia cell 
lines and this was compared to the readily available V-ATP-ase inhibitor bafilomycin A1 (44)33 
since salicylihalamide (31) was not available (Figure 6). Analogue 2 was 10 times less active on 
average than bafilomycin A1 (44) but in a linear relationship, suggesting analogue 2 has the same 
mode of action. 
 
  
Figure 6. Sensitivity of various leukemia cell lines to 15-aza-salicylihalamide analogue 2 versus bafilomycin A1 (44).8 
 
Migrastatin macrolactam (3) 
 Migrastatin (45) is a novel 14-membered macrolide from Streptomyces sp. MK929-43F and is a 
potent inhibitor of tumor cell migration, invasion and metastasis.7  A series of analogs with 
enhanced tumor cell migration inhibitory properties have been synthesized and their biological 
activities investigated by in vitro and in vivo studies. Danishefsky and co-workers9, 34  synthesized 
the aza migrastatin lactam analogue (3) according to the retrosynthesis in Scheme 6 based on their 
total synthesis of migrastatin.35 The key intermediates amine 47 and acid 46 were utilized to 
generate the macrolactam analogue 3 (Scheme 6) by a diverted total synthesis (DTS) approach. 
Murphy and co-workers also reported the synthesis of a related aza migrastatin analogue 48 using a 
similar synthetic approach.36 A 1 µM dose of analogue 48 inhibited migration of gastric cancer cells 
by up to 50% in a trans-well cellular locomotion assay. 
 
 Scheme 6. Strategy for the synthesis of aza-migrastatin analogue 3. 
 
 A stereoselective hetero-Diels-Alder reaction37 between aldehyde 49 and diene 50 followed by 
hydrolysis with TFA gave enone 51 in good yield as a single diastereoisomer. Reduction and 
hydrolysis followed by further reduction gave the primary alcohol 52, which was a key intermediate 
in the total synthesis of migrastatin (45). Selective protection provided an alcohol that was 
converted into the amine 47. Coupling with acid 46 provided diene 53. The synthetic macrolide was 
prepared by ring closing metathesis of the diene 53 using Grubbs-II catalyst and deprotection gave 
the aza-migrastatin analogue 3 which showed better activity against the 4T1 breast cancer cell line 
than migrastatin (45) (IC50 = 0.255 µM for 3 vs. 29 µM for 45). Mice injected with 4T1 cells 
showed that lactam 3 was also active against human colon tumor LOVO cells (IC50 = 0.174 µM) 
Cell line 
 
 Aza- analogue 2 
IC50 (nM) 
Bafilomycin A1 
(44) (nM) 
IC  (nM) CCRF-CEM 371 30  
HL-60 116 17 
K562 506 43 
MOLT-4 277 23 
RPMI-8226 117 13 
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and prostate tumor PC-3 cells (IC50 = 1.285 µM).
34b In addition, mice implanted with 4T1 cells that 
were injected with 10 mgkg-1 of lactam 3 daily had a 91-99% reduction in the numbers of 
metastasized 4T1 cells in the lung after 20 days when compared to control mice. 
 
 
Scheme 7. The synthesis of migrastatin analogue 3 from the migrastatin by a DTS approach.9 
 
Radicicol macrolactam analogues  
 The essential chaperone heat shock protein 90 (Hsp90) is one of the most common of its type 
found in eukaryotic cells and captures the energy from ATP-hydrolysis to promote the folding or 
stabilization of client proteins. Its function and importance has been implicated in diverse diseases 
including processes in oncogenesis such as self-sufficiency in growth signals.10 Hsp90 is an 
important host factor, promoting several steps of the HIV-1 life cycle,38 malaria39 and Alzheimer’s 
disease.40, 42 The overexpression of Hsp90 in tumors by some 2~10-fold and its ability to control the 
stability and activity of oncogenic proteins, makes targeting HSP90 an attractive anticancer 
strategy. Consequently Hsp90 inhibitors have emerged as a promising therapeutic intervention for a 
wide variety of human cancers in the past two decades.  
 
 
Figure 7. Radicicol (54) the macrolactone analogue 55 and aza analogues 56 and 4  
(TR-FRET and FP assays measure binding of compounds to human Hsp90β)10 
(GI50 against a human colon cancer cell line HCT116)
10 
 
 Radicicol (54) is a 14-membered resorcylic acid lactone macrolide isolated form various fungi41 
and is a potent in vitro Hsp90 inhibitor (IC50 = 20-23 nM) in cell lines (Figure 7).
42  However it 
exhibits no in vivo activity and this may be attributed to its highly reactive epoxide ring, the 
conjugated dienone system Michael acceptor and the macrolactone, all of which are easily 
metabolised. Consequently, the challenge has focused on the chemical synthesis of analogues with 
high activity and metabolic stability and a number of groups have reported the studies towards the 
synthesis of radicicol lactam analogues.10, 43 Whilst 12, 13 or 16 membered ring radicicol lactone 
analogues showed reduced activities,44 analogues with 14 or 15-membered rings, including the 
removal of the diene system, and replacement of the epoxide by a double bond were the most potent 
Hsp90 inhibitors10  (Figure 7). Moody and co-workers reported that the novel macrolactone 55 and 
macrolactam analogue 56 show comparable activity against human colon cancer cell lines.10, 43a The 
benzylamide analogue 410 exhibited at least a 10-fold higher antiproliferative activity than the 
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analogues 55 and 56 against human colon cancer  and was a 4 fold better binder according to TR-
FRET assays (IC50 = 80 nM vs IC50 = 350 nM for 55 and IC50 = 220 nM for 56). 
 
 
Scheme 8. The synthesis of radicicol lactam analogues 4, 56 and 61. 
 
 The synthesis of lactam analogues 4 and 56 is outlined in Scheme 8 and begins with the coupling 
of 57 and pentenyl malonyl chloride to afford ester 58. Ring-opening with amino-3-butene gave 
amide 59 which underwent RCM using Grubbs II catalysts to give the E-macrolactam 60 as the 
major geometric isomer. Hydrolysis followed by decarboxylation and MOM group removal gave 
the aza-radicicol analogue 56. Alternatively, removal of the MOM ethers from 60 afforded ester 
analogue 61 which was a strong binder to Hsp90 and had potent activity against HCT116 
comparable to analogue 4. Activation of the ester as the benzotriazole 62 and displacement with 
benzyl amine followed by MOM ether removal afforded the aza-radicicol analogue 4. Gratifyingly, 
macrolactam 56 was metabolically more stable than the lactones with 43% metabolized by human 
liver microsomes (after 30 mins) compared to 83% for radicicol 54, and 90% for the macrolactone 
analogue 55.43a 
  
 
 
Scheme 9. The synthetic route to N-methyl radicicol macrolactam analogues 
 
 A modified synthetic route to generate 14, 15 and 16-membered N-methyl radicicol macrolactam 
analogues is outlined in Scheme 9. Benzylic acylation of 63 with Weinreb amide 64 gave ketone 65 
but satisfactory reaction yields were achieved only when the acylation reaction was performed at a 
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minimum scale of 0.5 mmol of acid 63 at concentration 0.2M in THF at -78. Amide coupling with 
secondary amine 66 using HATU and Hünig’s base provided the diene 67 in 33% yield. As 
expected, a mixture of E/Z-isomers favoring E isomer 68 was obtained for the ring closing 
metathesis of 67 with Grubbs-II. Trifluoroacetic acid deprotection of 68 provided the N-methyl 
macrolactam 69 with overall yields of up to 12% from 63. Interestingly, removal of the 
ethoxymethyl groups from the two phenol groups, then the subsequent RCM was found to 
appreciably change the E/Z-isomer ratios of the macrolactam products. This synthetic strategy was 
utilized to generate N-methyl radicicol 15 and 16-membered ring macrolactam analogues 70 and 71. 
Surprisingly, N-methyl lactams 69-71 are much weaker binders to Hsp90 and exhibit greatly 
reduced potency against HCT116 (Scheme 9).10, 43a 
 
Radicicol Lactam Analogues: Binding Studies 
 
 The thermodynamics of binding to Hsp90 N-terminal domain showed that although the 
macrolactams were often better binders than the macrolactone analogues,43a, 44 the natural product 
radicicol (54) was the best (see Figure 6) implying that the epoxide ring exerts a unique binding and 
conformational interaction with the Hsp90 backbone that is not replicated by the macrolactams.  
Protein X-ray crystallography showed that radicicol 54 binds to the N-terminal domain ATP site of 
the Hsp90 molecular chaperone with the macrolactone ring in a puckered conformation locked by a 
key interaction between Lys44 and the epoxide (Figure 8A).45 The macrolactone analogue 55 binds 
to Hsp90 in a very similar manner however without the epoxide there is no interaction with 
Lys44.44 This contributes to the fact that lactone 55 is at least an order of magnitude less effective at 
binding to Hsp90. 
  
    A       B 
Figure 8. (A) Surface map of radicicol (yellow C atoms)  54 bound to N-terminal domain of yeast Hsp90 showing key 
H-bond interactions with water molecules represented by red spheres and H-bonds as black dashed lines (produced 
from X-ray structure from PDB code 1bgq see Pearl et. al.45)  
(B) Surface map of lactone 55 bound to Hsp90 showing key interactions (produced from X-ray structure from PDB 
code 2cgf see Moody et. al.44) 
  
 Moody and co-workers also demonstrated that macrolactams 56 and 4 are strong binders to 
Hsp90 and this was also studied by X-ray crystallographic analysis.10 The macrocyclic lactam 56 
binds to Hsp90 with the aromatic ring in the same binding pocket as radicicol (54) and lactone 55 
but with the macrolactam ring more flattened (Figure 9A). Lactam 4 also bound to Hsp90 in a 
similar manner but with an additional unusual binding of the benzyl amide group via a hydrophobic 
pocket (lined by residues Met84, Asn92, Leu93, Phe124, Val136, Trp148 and Leu173) and 
displacing the loop between Leu93 and Lys98 (Figure 9B).10 Analogue 4 depletes the representative 
client Hsp90 proteins C-RAF, ERBB2, and CDK4 and upregulates Hsp72 demonstrating that it acts 
as a Hsp90 inhibitior in the colon cancer cells assays. Thus, the unusual binding of the N-
benzylamide in 4 (Figure 8B) to the Hsp90 protein may explain its enhanced biological effects 
(Figure 7). 
  
Leu34
Lys44
Gly83
Asp79
Thr171
54
Asn92
Leu93
Phe124
Gly83
Asp79
Lys44
Leu34
Asn92
Leu93
Phe124
Thr171
55
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    A       B 
Figure 9. (A) Surface map of lactam 56 bound to Hsp90 showing key interactions (produced from X-ray structure from 
PDB code 2xx2 see Moody et. al.10) 
(B) Surface map of aza-radicicol analogue 4 bound to Hsp90 showing selected H-bonds and the N-benzyl group in the 
key hydrophobic pocket (produced from X-ray structure from PDB code 2xx5 see Moody et. al.10) 
 
 The X-ray structure of lactams 61 and 70 bound to Hsp90 (Figure 10) revealed that the key H-
bond interactions were similar to those observed for bound lactams 4 and 56 and the macrocyclic 
ring is again flattened and the ketone carbonyl oriented endo. For lactam 61, the ester group makes 
additional contacts not observed in lactam 56 (Figure 10A)  There is extra H-bonding of the ester 
via a water molecule to the carbonyl group Phe124 and Asp37. The lactam nitrogen has a contact 
via water molecule to the ketone carbonyl. For lactam 70, the N-methyl group of the lactam 
nitrogen points out of the binding pocket and the ketone carbonyl is pushed further away, thus 
explaining the more flattened macrocycle in the bound conformer (Figure 10B). In addition, the 
lactam N contacts are not present and this could explain the poor binding of this analogue compared 
to lactams 4, 56 and 61. 
 
  
    A       B 
Figure 10. (A) Surface map of lactam 61 bound to N-terminal domain of yeast Hsp90 showing key interactions.  
(produced from X-ray structure from PDB code 2xx4 see Moody et. al.10) 
(B) Surface map of lactam 70 bound to N-terminal domain of yeast Hsp90 showing key interactions.  (produced from 
X-ray structure from PDB code 4ce2 see Moody et. al.43a) 
 
 As shown in Figure 11A, a comparison of the bound conformations of radicicol (54) and lactone 
analogue 55 shows that they are very similar with both in a puckered or ‘L-shaped’46 conformation 
with the ketone oriented exo. Winssinger and co-workers used molecular dynamics calculations to 
show that the L-shaped bound conformer of 54 is the lowest in energy with the flattened or P-
shaped conformer higher in energy and an alternative L’-shaped conformer (macrocycle on the 
opposite side with respect to the benzene ring) the most energetic conformer.46 The bound 
conformer of lactam 56 (Figure 11B) is more P-shaped (planar), with the orientation of the ketone 
endo. This suggests that that the stronger binding of radicicol 54 can be attributed with the 
Phe124
Leu93
Asn92
Asn37
Leu34
Asp79
Thr171
Lys44
Leu173
Met84
56
Phe124
Trp148
Leu93
Asn92
Asn37
Asp79
Lys44
Val136
Leu173
Met84
Thr171
4
Phe124
Leu93
Asn92
Asn37
Asp79
Asp40
Lys44Met84
61
Leu34
Leu77
Gly83
Asp79
Lys44
Asp40
Asn92
Phe124
Thr171
70
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macrocycle in a more compact L-shaped conformation. Lactam 4 (Figure 11C) also binds in a 
similar manner to analogue 56 with the ketone endo but the extra hydrophobic binding of the benzyl 
amide increases the binding affinity with the macrolactam ring P-shaped conformation having less 
effect in this novel binding mode. The last example is lactam 70 compared to 54 (Figure 11D) in 
which the macrolactam ring is the most P-shaped conformation of all the examples presented. This 
may explain why the N-methyl lactam analogues 69-71 are poor binders to Hsp90 compared to the 
other macrolactams without N methylation. All the bound conformers of the lactam analogues 4, 56, 
61 and 70 have the ketone oriented endo and therefore cis to the amide NH or N-methyl group. 
There are extra H-bonds present for the amide NH and ketone in binding to Hsp90 which may 
contribute to their overall better affinity than the lactone 55, even though this is in a similar 
conformation as for radicicol (54). Thus, the H-bond to the epoxide in bound radicicol which is not 
present for 55 is compensated somewhat by the lactam analogues by interactions involving the 
lactam nitrogen atom and the ketone carbonyl group. 
 
 
   A   B   C   D 
 
Figure 11. Superimposed bound conformations of radicicol 54 (green) (A) with lactone analogue 55 (red), 
(B) lactam 56 (blue), (C) lactam 4 (purple) and (D) lactam 70 (orange). 
 
Pochoxime D lactam analogue 74 
 The natural product pochonin D (72) is structurally similar to radicicol but does not possess the 
labile epoxide and was also identified as a good Hsp90 binder by Winssinger et. al (Figure 12).46 
The oxime analogue 73 was found to possess better binding affinity for Hsp90 than the natural 
product 72, possibly due to the fact that the oxime has reduced electrophilicity compared to the 
ketone, making the oxime analogue a less efficient Michael acceptor and therefore less prone to 
degradation.46 
 
 
Figure 12. Pochonin D (72) and the macrolactone analogue 73 and aza analogue 74  
 
 Using a solid phase high throughput approach, the macrolactam pochoxime D analogue 74 was 
synthesised as outlined in Scheme 10.43b Addition of the benzylic anion derived from 75 to the 
Weinreb amide 76 followed by oxime formation gave acid 77. This was attached to solid phase via 
a chlorotrityl ether linkage and subjected to Tmse group removal with TBAF to afford 78. Coupling 
of acid 78 with the amine 79 and RCM using Grubbs II catalyst gave macrolactam 80 and cleavage 
from the linker, amide coupling and ethoxyethyl group removal with solid phase sulfonic acid gave 
analogue 74. Lactam analogue 74 was a stonger binder to Hsp90 than pochonin D (72) but a weaker 
binder (5 times less active) compared to the pochonin D analogue 73.47 
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Scheme 10. The synthetic route to macrolactam pochoxime analogue 74. 
 
Aza derivatives of macrolide antibiotics 
Antiobiotic macrolide A26771B lactam analogues 76 and 77.  
 
 
Figure 13. Antibiotic A26771B (75) and the lactam analogues 76 and 77. 
 
The macrolide (–)-A26771B (75) was isolated from Penicillium turbatum and showed promise as a 
new class of antibiotic (Figure 13).48 Although compound 75 exhibited moderate in vivo activity it 
was inactive against Staphylococcus aureus and Streptococcus pyogenes infections in mice. This 
inactivity was attributed to the instability of the macrolactone and succinate half ester and a number 
of derivatives were synthesized.49 The lactam analogues 76 and 77 were identified as promising  
antibiotics and the synthesis of these stereoisomers is shown in Scheme 11. 
 
 
 
Scheme 11. Synthesis of the A26771B (75)  macrolactam analogues 76 and 77. 
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 Treatment of the mesylate derived from serine derivative 78 with Grignard reagent 79 afforded 
the alkene 80. Addition of the same Grignard reagent to aldehyde 81 and methylation gave the 
racemic ether 82. A cross metathesis between 80 and 82 mediated by Grubbs I catalysts gave alkene 
83 as a mixture of four stereoisomers. Hydrogenation followed by oxidative furan ring opening 
gave aldehyde 84 which was oxidized to acid 85. Boc group removal and macrolactamisation gave 
the lactam diastereoisomers 76 and 77 in low yield which were separated by flash chromatography 
but not fully assigned. 
 Evaluation of analogues 76 and 77 against a panel of bacterial strains showed that they were both 
essentially identical in their activity and almost always more active than the natural product 75. 
Both 76 and 77 had MIC values of 2 µgml–1 against Enterococcus faecalis whilst A26771B (75) 
displayed an MIC value of 16 µgml–1. Analogues 76 and 77 were also more active than 75 against 
strains of Staphylococcus aureus (MIC 1 vs 4 µgml–1), Streptococcus pneumonia (MIC 2 µM vs 16 
µgml–1) and Enterococcus faecium (MIC 0.5 vs 4 µgml–1). More interestingly, 76 and 77 were 
active against Haemophilus influenzae ATCC 31517 (MIC 2 µgml–1) and H. influenza LS2 Efflux 
Knock-out (MIC 0.25 µgml–1) whilst the natural product 75 was far less active (MIC >32 µgml–1). 
Importantly, The macrolactam analogues remained active in the presence of 10% human serum in 
the Staphylococcus aureus assay (MIC 8 µgml–1) while the macrolactone natural product 75 was 
inactive clearly demonstrating the stability of the macrolactam in human serum.  Unfortunately, 
macrolactams 76 and 77 were orally inactive in a mouse lung infection model at a dose of 50 mgkg–
1. 
 
Glycosylated macrolactam analogues of the macrolide antibiotic YC-17 (87) 
 The 14-membered macrolide erythromycin (86)50 has long been an effective orally active 
treatment for bacterial infections and many derivatives have also been successful as antibiotics 
however, the complex nature of these compounds make them difficult to functionalise as 
macrolactam derivatives (Figure 14). The less complex 12-membered macrolide antibiotic YC-17 
(87), isolated from Streptomyces venezuelae ATCC 15439,51 was therefore targeted for aza-
analogue synthesis and the macrolactam aglycone aza-10-deoxymethynolide (AZDM) (88) was 
synthesized along with the glycosylated derivatives L-rhamnosyl-AZDM (89) and D-quinovosyl-
AZDM (90) (both produced from 88 by chemoezymatic synthesis).52 
 
 
Figure 14. Antibiotics erythromycin (86) and YC-17 (87) and the AZDM (88) glycoside analogues 89 and 90. 
 
 The synthesis of AZDM (88) is depicted in Scheme 12 and begins with the coupling of amine 91 
with acid 9253 mediated by EDC•HCl and HOBt to afford amide 93. Selective primary TBS group 
removal and oxidation with Dess-Martin periodinane gave the aldehyde 94 which upon treatment 
with vinyl magnesium bromide and oxidation yielded enone 95. RCM using Grubbs II catalyst gave 
the macrolactam 96 in good yield as the E-isomer and deprotection gave AZDM (88). 
Chemoezymatic glycosylation of synthetic 88 incubation with a mutant strain of S. venezuelae 
YJ028 in which the gene cluster for encoding the pikromycin PKS and desosamine biosynthetic 
enzymes were deleted (pLRHM2 expressing thymidine diphosphate (TDP) L-rhamnose 
biosynthetic genes with glycosyltransferase DesVII/DesVIII) afforded low yields of both L-
rhamnosyl-AZDM (89) (1.4 mg from 2.4 L culture) and D-quinovosyl-AZDM (90).52 The 
production of 90 by this process was attributed to the fact that TDP-4-keto-6-deoxy-D-glucose, 
which is a biosynthetic intermediate of TDP-L-rhamnose, can be reduced with S. venezuelae 4-
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ketoreductase to produce TDP-D-quinovose than then glycosylates AZDM (88). D-Quinovosyl-
AZDM (90) (0.3 mg from 1.8 L culture) could also be produced by incubation of 88 with mutant 
YJ028/pDQNV harboring the D-quinovose biosynthetic genes. 
 
Scheme 12. Synthesis of the ADZM macrolactam glycosides 89 and 90. 
 
 Both lactam glycoside analogues 89 and 90 were at least 4 times more active against several 
bacterial strains in vitro than erythromycin (86) (Table 1).52 In addition, the macrolactam 89 was 
much more stable to the macrolide esterase EreB (isolated from the erythromycin-resistant 
Escherichia coli) than erythromycin (86). After 1h incubation with EreB, erythromycin (86) was 
completely converted to the linear erthythromycin inactivation product while L-rhamnosyl-AZDM 
(89) remained intact, even after 24h incubation. This clearly shows that the macrolactam analogues 
of AZDM glycosides are stable to bacterial esterases and are active against erythromycin-resistant 
pathogens. In addition, macrolactam 89 was shown to be stable on exposure to simulated gastric 
fluid (SGF). Incubation of erythromycin (86) with SGF resulted in complete degradation to 5-
desosaminylerythronolide A in 2 h but macrolactam 89 remained intact after incubation with SGF 
over the same time period. Incubation of erythromycin (86) or macrolactam 89 with rat liver 
microsomes and NADPH for 2 h resulted in degradation of the former compound whilst 89 
remained unchanged. Finally, both compounds 89 and 90 showed low cytotoxicity against human 
cell line HEK293 (IC50 > 50 µmol) making them good candidates for further clinical development. 
 
Compound 
 
 E. faecium 
ATCC19434 
E. faecium 
E. faecium 
P00558 
S. aureus 
ATCC2592
3 
S. aureus 
P00740 
Erythromycin (86) 30.0 >120.0 60.0 120.0  
L-Rhamnosyl-AZDM (89) 7.5  30.0  15.0 30.0 
D-Quinovosyl-AZDM (90) 7.5 30.0 15.0 30.0 
 
Table 1. Antibacterial activities [MIC (µM)] of erythromycin (86), L-rhamnosyl-AZDM (89) and D-quinovosyl-AZDM 
(90). 
 
Conclusion 
 The lactam analogue of the myxobacteria metabolite epothilone B (5), namely ixabepilone (1), is 
the benchmark for aza modified macrolides. This great success story, starting with the isolation of 
the natural product, biological assay, SAR and analogue preparation and final clinical application is 
a key example of how this simple aza modification of macrolides can provide useful active 
analogues. Inspired by this success, the synthesis of other examples of aza analogues of macrolide 
natural products has been pursued by a number of research groups.  Macrolactam analogues based 
on the marine macrolide salicylihalamide (31), bacterial metabolite migrastatin (45), fungal 
metabolite radicicol (54) and antibiotic macrolides A26771B (75) and YC-17 (87) presented in this 
review show that significant biological and chemical properties such as metabolic stability, reduced 
toxicity, protein binding and desirable macrocyclic conformations can be achieved. Thus, the 
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modification of the macrolactone to a macrolactam imparts a number of desirable properties apart 
from derivatives simply being less susceptible to hydrolysis With the further development of 
efficient synthetic technologies for macrolactam formation, natural product aza analogues will be 
even more readily accessible and destined to result in improved therapeutics.  
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